TAT-AKAP79 (326-336) scrambled YGRKKRRQRRRKEMRESKESKS-acid

  • Description

  • Application Data

Description

Tat domain conjugated to the sequence of A-kinase anchoring protein 79 (AKAP79) mapped to bind to TRPV1 with the key residues reordered. C-terminal acid.

See full description

Application Data

Catalogue number crb1001278
Molecular Weight 2878.6
Sequence (one letter code) YGRKKRRQRRRKEMRESKESKS-acid
Sequence (three letter code)

H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Glu-Met-Arg-Glu-Ser-Lys-Glu-Ser-Lys-Ser-OH

Purity >95%
Storage -20°C
References

Btesh et al., (2013) Mapping the Binding Site of TRPV1 on AKAP79: Implications for Inflammatory Hyperalgesia. J. Neurosci. 33(21): 9184. https://doi.org/10.1523/JNEUROSCI.4991-12.2013.

 

Du et al., (2019) The Role of Transient Receptor Potential Vanilloid 1 in Common Diseases of the Digestive Tract and the Cardiovascular and Respiratory System. Front. Physiol. 10: 1064. https://doi.org/10.3389/fphys.2019.01064.

Manufactured in: United Kingdom
Data Sheet Material Safety Data Sheet (MSDS)

The activation of transient receptor potential cation channel subfamily V member 1 (TRPV1) is believed to play a role in hyperalgesia, asthma and hypertension. TRPV1 is important for neuronal pain detection as well as the detection of heat, capsaicin, protons and the neurotransmitter anandamide.  The scaffold protein AKAP79 targets kinases to phosphorylate TRPV1, however it has been shown that inflammatory intermediates prostaglandin-E2 or bradykinin can activate these kinases creating a route for inflammation to cause hyperalgesia.

This product is composed of the TRPV1 interacting domain of AKAP79 reordered into a scrambled sequence and conjugated to the cell penetrating TAT domain. This product was shown in vivo to have no effect on TRPV1 algesia and thus is a vital control for research work. This product is a vital tool for research into suitable TRPV1 antagonists.

TAT-AKAP79 (326-336) scrambled

Cat No.Pack SizePriceQty.
0.5mg£85.00
1mg£110.00
Bulk Quote